

For episodes of frequent seizure activity



TEAM UP

with VALTOCO® (diazepam nasal spray)



Together, we can change the seizure rescue experience at school

VALTOCO is the ONLY nasal seizure rescue medication for students 6 years and older with episodes of frequent seizure activity.^{1,2}

- ◆ The medication you know* is available in a **RELIABLE and DISCREET** nasal spray
- ◆ **PROVEN** safety and tolerability for peace of mind
- ◆ Designed for **PROMPT** administration by anyone, anywhere—from the classroom to the playground[†]
- ◆ **EASY-TO-USE** nasal spray that's **READY** at a moment's notice
- ◆ **EMPOWERS** nurses like you, teachers, and other staff members to administer VALTOCO confidently

“*The most effective action plan will include the least restrictive medication choice (buccal or nasal rather than rectal) in the child's environment.*”

— NASN School Nursing Evidence-Based Clinical Practice Guideline: Students With Seizures and Epilepsy³

*Diazepam is the active ingredient in diazepam rectal gel and VALTOCO.

[†]Patients and care partners should read the Instructions for Use that come with VALTOCO before using it.

Advocate for THE COMPASSIONATE CHOICE for your students this school year

Indication

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

• Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Please see reverse for continued Boxed Warning and additional important safety information, and read accompanying full Prescribing Information.

 **VALTOCO®**
(diazepam nasal spray) ©

Contact myNEURELIS at
1-866-myNEURELIS (1-866-696-3873)
or visit **myNEURELIS.com**.

Flexible support for you

Through myNEURELIS, you can connect with a registered nurse educator for one-on-one instruction. myNEURELIS nurse educators can:

- ◆ Provide virtual training on how to give VALTOCO (diazepam nasal spray)
- ◆ Answer VALTOCO-related questions
- ◆ Send you a training device

Personalized support is also available for your students and their care partners.

Download VALTOCO resources and tools for school nurses by scanning the QR code or visiting VALTOCOHCP.com.



Scan using the camera on your smartphone.

IMPORTANT SAFETY INFORMATION (CONT.)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS (CONT.)

- The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.
- The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

Contraindications: VALTOCO is contraindicated in patients with:

- Hypersensitivity to diazepam
- Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including "gaspings syndrome", can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The "gaspings syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read accompanying full Prescribing Information, including Boxed Warning, for additional important safety information.

References: 1. VALTOCO® (diazepam nasal spray) Prescribing Information. Neurelis, Inc. 2. VALTOCO® (diazepam nasal spray) Instructions for Use. Neurelis, Inc. 3. Lepkowski A. *School Nursing Evidence-Based Clinical Practice Guideline: Students With Seizures and Epilepsy*. National Association of School Nurses; 2018.